Long-Acting Immune Cells May be Key to Effective Vaccines

The COVID-19 pandemic highlighted the variability in vaccine efficacy, with regular booster shots needed to maintain immunity against the SARS-CoV-2 virus. In contrast, a single vaccination against measles can confer protection that lasts for decades. The reason for this discrepancy has long been a mystery to scientists. However, a recent study by Prof. David Tarlinton and Dr. Marcus Robinson at Monash University in Australia uncovered a clue that could impact vaccine development.

According to the researchers, a specific type of immune cell that generates antibodies over time is crucial for maintaining long-lasting immunity. The scientists followed antibody-secreting cells in an animal model and discovered specific markers that indicated how long they lived. They used a method called “timestamping” to measure how often these cells were replaced and found that only a small percentage of them survived for more than 60 days.

The study revealed that long-lived antibody-secreting cells have a distinct gene signature and pattern of surface markers, which suggests that longevity is programmed into the cell. These are the cells that need to be targeted when developing vaccines that provide long-lasting protection. The researchers also found that there is a maximum number of these long-lasting antibody-secreting cells that the body can hold at any one time. Therefore, improved vaccines must focus on maintaining these reservoirs of long-acting cells.

The research findings suggest that the longevity of antibody-secreting cells is not determined by isotype but by the underlying gene signature and surface markers. While some of these markers are acquired with age, others are shared by younger antibody-secreting cells, such as high CD138 and CD93. The study also found that altered antibody-secreting cell production does not affect turnover, arguing against competition for niches as a significant turnover driver. Instead, turnover is set by intrinsic lifespan limits, with steady-state population dynamics governed by niche vacancy rather than displacement.

These findings, published in Immunity, could have significant implications for vaccine development. Vaccines that can generate a unique subtype of immune cell producing antibodies could provide longer-lasting protection against infectious diseases. The study also highlights the importance of maintaining the reservoirs of long-acting cells to ensure sustained immunity. This could be achieved through the development of new adjuvants, which are substances that enhance the body’s immune response to vaccines.